drugset
drugset / Trial / NCT04066712

Renal PK Study of LC350189

NCT04066712 ↗

Phase 1 Completed 37 enrolled LG Chem
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a Phase 1, open-label, parallel-group, multiple-dose study designed to assess the effect of renal impairment on the PK and PD of LC350189.

Timeline

Start
2019-11-19
Primary completion
2020-09-12
Completion
2020-09-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Tigulixostat Small molecule 200 mg Oral

Indications

gout